LumaCyte

LumaCyte

Private
Charlottesville, VirginiaHealthcare & Life Scienceshttps://www.lumacyte.com/

Last Round

Series B

Sep 6, 2023

Total Funding Raised

$12.67M

Momentum Score

25 /100

Company Overview

LumaCyte is a bioanalytics instrumentation company that produces label-free, single cell analysis instrumentation for research and biomanufacturing applications.

Sector

Healthcare & Life Sciences

Verticals

Biotech Equipment, Healthcare Analytics, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales, Hardware + Subscription, Subscription SaaS, Services & Consulting, Government Contracts

AI Layer

Application

Keywords

single-cell analysislabel-free cell analysisbioanalytics instrumentationLaser Force CytologyLFCcell therapygene therapyvaccine developmentflow cytometry alternativeprocess analytical technologyPATbiophysical cytometrycell characterizationbiomanufacturingCAR T-cell therapycell potency assayquality controldrug discoveryCDMO

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

LumaCyte Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

LumaCyte Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series BSep 6, 2023
Series AMar 2, 2022
GrantAug 30, 2019
GrantJan 9, 2019
GrantApr 1, 2018

Key People

Founding team and executive leadership

Sean Hart

Chief Executive Officer & Chief Scientific Officer, Chairman Of The Board Of Directors

Executive Team

Renee A. Hart

President & Chief Business Officer, Managing Member, Board Of Directors

Executive Team

LumaCyte Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 17, 2026

    Grew 20% QoQ, from 20 to 24 employees.

  • Nov 27, 2023

    Grew 20% QoQ, from 20 to 24 employees.

LumaCyte Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

LumaCyte Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about LumaCyte's valuation, stock price, and market status.

Firmographic Details

HeadquartersCharlottesville, Virginia
Employee Range24
Year Founded2012
Last FundingSep 6, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.